AKYA - Akoya Biosciences, Inc. Stock Price, Fair Value and News

2.45USD+0.01 (+0.41%)Market Closed

Market Summary

USD2.45+0.01

Market Closed

0.41%

AKYA Stock Price

View Fullscreen

AKYA RSI Chart

AKYA Valuation

Market Cap

121.0M

Price/Earnings (Trailing)

-1.78

Price/Sales (Trailing)

1.29

EV/EBITDA

-3.54

Price/Free Cashflow

-2.18

AKYA Price/Sales (Trailing)

AKYA Profitability

Operating Margin

55.99%

EBT Margin

-72.60%

Return on Equity

-207.82%

Return on Assets

-43.95%

Free Cashflow Yield

-45.97%

AKYA Fundamentals

AKYA Revenue

Revenue (TTM)

93.6M

Rev. Growth (Yr)

-14.29%

Rev. Growth (Qtr)

-30.72%

AKYA Earnings

Earnings (TTM)

-68.0M

Earnings Growth (Yr)

-24.9%

Earnings Growth (Qtr)

-117.4%

Breaking Down AKYA Revenue

Last 7 days

1.2%

Last 30 days

3.4%

Last 90 days

-35.8%

Trailing 12 Months

-65.0%

How does AKYA drawdown profile look like?

AKYA Financial Health

Current Ratio

3.07

Debt/Equity

2.31

Debt/Cashflow

-0.69

AKYA Investor Care

Shares Dilution (1Y)

28.59%

Diluted EPS (TTM)

-1.67

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2024	93.6M	0	0	0
2023	79.4M	85.0M	91.4M	96.6M
2022	59.6M	64.4M	69.8M	74.9M
2021	43.6M	48.1M	51.7M	54.9M
2020	0	0	0	42.4M

Get all data in R, Python etc through our Historical Stock Data APIs

About Akoya Biosciences, Inc.

Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions focused on transforming discovery and clinical research in North America, the Asia Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImager platform that enables researchers to visualize, analyze, quantify, and phenotype cells in situ, in fresh frozen or FFPE tissue sections, and tissue microarrays utilizing an automated and high-throughput workflow. It also provides PhenoCycler and PhenoImager reagents; and biopharma services. In addition, the company offers analysis software partnerships ecosystem; inForm Tissue, an automated image analysis software package for accurately visualizing and quantifying biomarkers in tissue sections; Phenoptr, which provides functions that consolidate and analyze output tables created by inForm software; and phenoptrReports, a software that generates shareable reports and visualizations based on the phenoptr output in an intuitive front-end GUI. The company was incorporated in 2015 and is headquartered in Marlborough, Massachusetts.

CEO	Mr. Brian McKelligon
WEBSITE	akoyabio.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	369

Akoya Biosciences, Inc. Frequently Asked Questions

What is the ticker symbol for Akoya Biosciences, Inc.? What does AKYA stand for in stocks?

AKYA is the stock ticker symbol of Akoya Biosciences, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Akoya Biosciences, Inc. (AKYA)?

As of Thu Jul 25 2024, market cap of Akoya Biosciences, Inc. is 120.5 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AKYA stock?

You can check AKYA's fair value in chart for subscribers.

Is Akoya Biosciences, Inc. a good stock to buy?

The fair value guage provides a quick view whether AKYA is over valued or under valued. Whether Akoya Biosciences, Inc. is cheap or expensive depends on the assumptions which impact Akoya Biosciences, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AKYA.

What is Akoya Biosciences, Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Thu Jul 25 2024, AKYA's PE ratio (Price to Earnings) is -1.77 and Price to Sales (PS) ratio is 1.29. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AKYA PE ratio will change depending on the future growth rate expectations of investors.